NMS·Healthcare·$1.9B·#298 / 520 in Healthcare
RXRX Recursion Pharmaceuticals, Inc.
39HIGH RISK
CATEGORY BREAKDOWN
GROWTH43
QUALITY4
STABILITY88
VALUATION5
GOVERNANCE16
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+27.0%
43
> 50% strong
Gross Margin
Revenue retained after direct costs
4.4%
6
> 50% strong
Cash Runway
Months of cash at current burn rate
24 months
85
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
6.9%
94
< 25% strong
Price / Sales
Market cap relative to trailing revenue
24.9x
5
< 3x strong
Rule of 40
Growth rate plus operating margin
-846
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
2.8%
23
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+28.4%
2
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE RXRX WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
4 Best Small-Cap AI Drug Discovery Stocks — May 2026May 4, 2026SCORE ALERT
Get notified when RXRX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.